An Open-Label, Multicentre Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Official Title

A Phase Ib/II Open-Label, Multicentre Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Summary:

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.

Trial Description

Primary Outcome:

• Percentage of Participants with Adverse Events (Phase 1b)
• Best Objective Response Rate (ORR) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 2)

• Best ORR as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b)
• Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b and Phase 2)
• Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 1b and Phase 2)
• Progression-Free Survival (PFS) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 2)
• Event-Free Survival (EFS) as Determined by the Investigator Using Lugano 2014 Criteria (Phase 2)
• Overall Survival (OS) (Phase 2)
• Percentage of Participants with Adverse Events (Phase 2)
• Serum Concentration of Mosunetuzumab
• Serum Concentration of Mosunetuzumab in Combination with Tiragolumab
• Serum Concentration of Mosunetuzumab in Combination with Tiragolumab and Atezolizumab

View this trial on ClinicalTrials.gov